Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer G Robinson

Showing results (11-20 of 259) with videos related to

Pageof 26
Sort By:
Current Cardiology Reports|October 28, 2008
LDL reduction: how low should we go and is it safe?Jennifer G Robinson
Current Atherosclerosis Reports|December 17, 2008
Is a statin as part of a polypill the answer?Jennifer G Robinson
Annals of Internal Medicine|September 16, 2015
Statins for Primary Prevention in Adults Aged 75 Years or OlderJennifer G Robinson
Current Opinion in Lipidology|April 19, 2015
Statins and diabetes risk: how real is it and what are the mechanisms?Jennifer G Robinson
Circulation|March 30, 2016
Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT"Jennifer G Robinson
European Heart Journal|March 31, 2016
Lower might be better - It matters how you get there, and in whomJennifer G Robinson
PPAR Research|February 22, 2008
Should We Use PPAR Agonists to Reduce Cardiovascular Risk?Jennifer G Robinson
Current Opinion in Lipidology|September 28, 2016
The future of lipid guidelinesJennifer G Robinson
Journal of the American College of Cardiology|April 15, 2017
Reply: Cost Effectiveness of Nonstatin-to-Statin TherapyJennifer G Robinson
Progress in Cardiovascular Diseases|August 8, 2016
Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial HypercholesterolemiaJennifer G Robinson
Pageof 26

Showing results (11-20 of 259) with videos related to

Sort By:
Pageof 26
Current Cardiology Reports|October 28, 2008
LDL reduction: how low should we go and is it safe?Jennifer G Robinson
Current Atherosclerosis Reports|December 17, 2008
Is a statin as part of a polypill the answer?Jennifer G Robinson
Annals of Internal Medicine|September 16, 2015
Statins for Primary Prevention in Adults Aged 75 Years or OlderJennifer G Robinson
Current Opinion in Lipidology|April 19, 2015
Statins and diabetes risk: how real is it and what are the mechanisms?Jennifer G Robinson
Circulation|March 30, 2016
Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT"Jennifer G Robinson
European Heart Journal|March 31, 2016
Lower might be better - It matters how you get there, and in whomJennifer G Robinson
PPAR Research|February 22, 2008
Should We Use PPAR Agonists to Reduce Cardiovascular Risk?Jennifer G Robinson
Current Opinion in Lipidology|September 28, 2016
The future of lipid guidelinesJennifer G Robinson
Journal of the American College of Cardiology|April 15, 2017
Reply: Cost Effectiveness of Nonstatin-to-Statin TherapyJennifer G Robinson
Progress in Cardiovascular Diseases|August 8, 2016
Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial HypercholesterolemiaJennifer G Robinson
Pageof 26